Type 2 diabetes incidence in patients initiating denosumab or alendronate treatment: a primary care cohort study
Main finding · T2DM incidence rate per 1,000 person-yearsResult — go to the resultHazard ratio 0.73 95% CI 0.58–0.89Authors' conclusion
In this comparative study of older patients seen in routine practices, denosumab was associated with a lower risk of developing T2DM than alendronate.
Study context
- Population
- Patients aged ≥ 45 years without history of diabetes initiating denosumab or alendronate (2010–2021), IQVIA Disease Analyzer general and specialist practices, Germany54,916 person-years
- Participants
- 3,354 vs 27,068
- Exposure
- Denosumab vs alendronate initiation
- Denosumabn = 3,354
- Alendronaten = 27,068reference
- Outcome
- Incident T2DM
Methodological detailsnew-user comparative study, primary care, Cox proportional hazards
- New-user comparative study
- Primary care
- Cox proportional hazards
Main finding
T2DM incidence rate per 1,000 person-years
Hazard ratio
0.73
95% CI 0.58–0.89
By group
Denosumabvs Alendronate
HR 0.73 (95% CI 0.58–0.89)
As reported in the abstract
Observational data: associations, not effects.
Original publication
Type 2 diabetes incidence in patients initiating denosumab or alendronate treatment: a primary care cohort study. Osteoporos Int. Published 24 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →